DEL MAR, Calif., March 20, 2024 (GLOBE NEWSWIRE) — Genece Health, a molecular testing company focused on improving cancer screening for lung, breast, ovarian and other cancers, today announced that four abstracts demonstrating their deep-learning AI and liquid biopsy technology’s performance were selected for presentation at the upcoming 2024 American Association for Cancer Research (AACR), taking place April 5-10, 2024, in San Diego, CA. This will be the first time performance data from the company will be shared publicly.
The abstracts will be available on the AACR website and poster presentation details can be found below.
Subject: Lung cancer test results show high sensitivity and specificity
Title: A Novel Liquid Biopsy Lung Cancer Detection Method Using a Coverage and Fragment End Motif Machine Learning Analysis
Session Title: Risk Prediction Modeling, Screening, Early Detection, and Preneoplastic and Tumor Markers
Location: Poster Section 33 Board 3
Abstract Number: 3448
Date/Time: Monday April 8, 1:30PM to 5:00PM
Presenting Author: Bryan Leatham
Subject: A powerful new Machine Learning approach to increase sensitivity
Title: REFINE Method: Novel Strategy for Signal Enhancement
Session Title: Artificial Intelligence and Machine/Deep Learning 3
Location: Poster Section 36 Board 24
Abstract Number: 4928
Date/Time: Tuesday April 9, 9:00AM to 12:30PM
Presenting Author: Michael Wang, PhD
Subject: Promising initial results in breast cancer for screening patients with dense breast tissue
Title: Improving Cancer Screening Performance for Women with Dense Breast Tissue
Session Title: Population-Based Screening
Location: Poster Section 32 Board 13
Abstract Number: 4796
Date/Time: Tuesday April 9, 9:00AM to 12:30PM
Presenting Author: Molly Smith
Subject: Robust performance even when cfDNA inputs decrease
Title: Optimization of a Liquid Biopsy Assay to Accommodate Low cfDNA Samples and Increase Throughput
Session Title: Advances in Genomic Sequencing Platforms, Methodologies, and Interpretation 1
Location: Poster Section 14 Board 11
Abstract Number: 323
Date/Time: Sunday April 7, 1:30PM to 5:00PM
Presenting Author: Michael Salmans, PhD
More information can be found on the AACR meeting website.
About Genece Health
Genece leverages a proprietary liquid biopsy and deep-learning AI technology for early cancer detection. The Company was founded in 2022 through a strategic partnership with GC Genome, the genomics arm of GC Corporation, a leading life sciences company in South Korea. Genece focuses on the acute need for targeted screening tools to support decision-making when a mass or lump is detected through imaging, empowering physicians to make informed decisions and improve care. The Company’s initial applications include high-mortality and women’s health cancers. For more information, visit genecehealth.com or follow Genece on Linkedin.
Investor Contact:
NEW YORK--(BUSINESS WIRE)--Vent Creativity, a medical technology company advancing AI-enabled surgical planning, today announced the…
AEON Clinic Elevates Dubai to Global Hub for Longevity Science, A Definitive Four-Day Summit Defining…
Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…
Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…
Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…
Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment Primeadine Longevity Shot Primeadine…